62.2 F
New York
Friday, September 24, 2021

Biofrontera [NASDAQ: BFRA] Announces Submission of Application for New BF-RhodoLED

Must read

XPeng [NYSE: XPEV] Backed HT Aero Launch Flying Vehicle City Usage Scenarios

XPeng Inc. disclosed that HT Aero has launched future urban usage scenarios for its fifth-generation flying vehicle XPeng X2 (X2). It includes independent...

Metrospaces Choose Cryptobucks as Preferred Cryptocurrency Partner

Metrospaces disclosed that it has selected Cryptobucks as its preferred cryptocurrency partner. It has inked an agreement to consolidate Cryptobucks into all of its...

Novartis [NYSE: NVS] Announces Acquisition of Arctos Medical

Novartis AG disclosed that it has acquired Arctos Medical. This purchase decision will add a pre-clinical optogenetics-based AAV gene therapy program and Arctos’...

Mastercard [NYSE: MA] Announces Launch of Sustainability Innovation Lab

Mastercard Incorporated has introduced a new sustainability innovation lab. The firm disclosed that its new lab will lead the further development of the...

Biofrontera AG [NASDAQ: BFRA] has disclosed that it has submitted an application for New BF-RhodoLED to FDA. The firm is seeking permission for the use of the BF-RhodoLED XL in combination with Ameluz from the FDA. The combination will be used for the cure of minor and reasonable actinic keratoses on the face and scalp.

This is consistent with the current authorization of Ameluz. The intention is to expand the label to include extra indications in the future. The new PDT lamp allows the cure of larger areas as well as the synchronized coverage of several actinic keratoses distant from each other.

The regulatory submission is unbiased of the change in product information presented to the FDA in February. It was presented to permit the use of three tubes of Ameluz per cure but adds it to cure larger areas. Presently, the product data and thus repayment is restricted to the use of one tube of Ameluz per cure.

The new lamp is protected by several patents before submission to the FDA. The cure settings of the new BF-RhodoLED, such as light dose, and wavelength of light are similar to the BF-RhodoLED.

More articles

Latest article

ReneSola [NYSE: SOL] and Eiffel’s Joint Venture Buys Its First 200 MW Project Portfolio

ReneSola Ltd disclosed that European Solar Energy Development JV has finalized the purchase of its first batch of solar projects with a combined...

Square [NYSE: SQ] Launch its Early Access Program in Spain

Square, Inc. which has earned a reputation as a software, payments, and hardware solution firm for all types of businesses disclosed that it...

Ideanomics [NASDAQ: IDEX] Decides to Increase Stake in Energica

Ideanomics, Inc. disclosed that it has decided to ink an agreement with Energica Company. As per the agreement, the firm has decided to...

L3Harris’ [NYSE: LHX] Robot Chosen to Protect US Air Force Bases Around the Globe

L3Harris Technologies, Inc. disclosed that it has received a huge contract from US Air Force. The firm revealed that its robot will now...

Tower Semiconductor [NASDAQ: TSEM] Introduces Breakthrough LiDAR Technology

Tower Semiconductor Ltd. has introduced a breakthrough development of LiDAR IC technology created for sophisticated driver-assistance systems (ADAS) and ultimately self-driving cars. The...

KKR [NYSE: KKR] Decides to Divest Riata Corporate Park

KKR & Co. Inc. has disclosed that it has decided to divest the Riata Corporate Park. Riata Corporate Park is an eight-building, 688,100...

3D Systems [NYSE: DDD] Unveil VisiJet Wax Jewel Red

3D Systems Corporation has launched the VisiJet Wax Jewel Red. It will allow jewelry makers to design and create more sophisticated, lasting patterns....

Xerox [NYSE: XRX] Announces Transfer of Stock Exchange Listing to Nasdaq from NYSE

Xerox Holdings Corporation has made an important announcement regarding its listing on Stock Exchange. The firm has revealed that it has decided to...